194 related articles for article (PubMed ID: 2550147)
1. Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms.
Kurakata S; Ramos OF; Klein G; Klein E
Cell Immunol; 1989 Oct; 123(1):134-47. PubMed ID: 2550147
[TBL] [Abstract][Full Text] [Related]
2. Activation and fixation of C3 by human B cell lines is enhanced by interferon-gamma and tumor necrosis factor alpha.
Yefenof E; Algarra I; Ramos OF; Klein E
Complement Inflamm; 1991; 8(5-6):271-80. PubMed ID: 1666351
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.
Sairenji T; Reisert PS; Spiro RC; Connolly T; Humphreys RE
J Exp Med; 1985 May; 161(5):1097-111. PubMed ID: 2580934
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.
Nemerow GR; Jensen FC; Cooper NR
J Clin Invest; 1982 Nov; 70(5):1081-91. PubMed ID: 6290536
[TBL] [Abstract][Full Text] [Related]
5. Induction of the EBV cycle in B-lymphocyte-derived lines is accompanied by increased natural killer (NK) sensitivity and the expression of EBV-related antigen(s) detected by the ADCC reaction.
Patarroyo M; Blazar B; Pearson G; Klein E; Klein G
Int J Cancer; 1980 Sep; 26(3):365-71. PubMed ID: 6270007
[TBL] [Abstract][Full Text] [Related]
6. Column separation of viral capsid antigen (VCA)-positive cells from VCA-negative cells in an Epstein-Barr virus (EBV)-producing lymphoid line,
Dalianis T; Klein G; Andersson B
Int J Cancer; 1977 Apr; 19(4):460-7. PubMed ID: 191413
[TBL] [Abstract][Full Text] [Related]
7. Recovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV.
Fresen KO; Cho MS; zur Hausen H
Int J Cancer; 1978 Oct; 22(4):378-83. PubMed ID: 212377
[TBL] [Abstract][Full Text] [Related]
8. Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
Gerber P; Ablashi D; Magrath I; Armstrong G; Andersen P; Trach L
J Natl Cancer Inst; 1982 Sep; 69(3):585-90. PubMed ID: 6287082
[TBL] [Abstract][Full Text] [Related]
9. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
Fresen KO; zur Hausen H
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
[TBL] [Abstract][Full Text] [Related]
10. Correlated expression of a B-lymphocyte-specific glycoprotein (gp27/35) and the EBV receptor/C3 receptor complex in sublines from the same Burkitt lymphoma.
Klein G; Hyman R; Trowbridge I
Int J Cancer; 1979 Jan; 23(1):37-41. PubMed ID: 215562
[TBL] [Abstract][Full Text] [Related]
11. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
Klein G; Ehlin-Henriksson B; Schlossman SF
J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
[TBL] [Abstract][Full Text] [Related]
12. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
[TBL] [Abstract][Full Text] [Related]
13. Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules.
Di Renzo L; Avila-Cariño J; Klein E
Immunol Lett; 1993 Nov; 38(3):207-14. PubMed ID: 8125529
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Epstein-Barr virus (EBV)-production and the loss of the EBV receptor/complement receptor complex in a series of sublines derived from the same original Burkitt's lymphoma.
Klein G; Yefenof E; Falk K; Westman A
Int J Cancer; 1978 May; 21(5):552-60. PubMed ID: 207646
[TBL] [Abstract][Full Text] [Related]
15. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
Klein G; Giovanella B; Westman A; Stehlin JS; Mumford D
Intervirology; 1975; 5(6):319-34. PubMed ID: 181343
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus (EBV)--lymphoid cell interactions. II. The influence of the EBV replication cycle on natural killing and antibody-dependent cellular cytotoxicity against EBV-infected cells.
Patel PC; Menezes J
Clin Exp Immunol; 1982 Jun; 48(3):589-601. PubMed ID: 6288292
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus antibodies in patients with ataxia-telangiectasia and other immunodeficiency diseases.
Joncas JH; Wills A; Reece E; Fox Z
Can Med Assoc J; 1981 Oct; 125(8):845-9. PubMed ID: 6272957
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles.
López-Montañés M; Alari-Pahissa E; Sintes J; Martínez-Rodríguez JE; Muntasell A; López-Botet M
J Immunol; 2017 Jul; 199(2):656-665. PubMed ID: 28630095
[TBL] [Abstract][Full Text] [Related]
19. Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV.
Klein G; Sugden B; Leibold W; Menezes J
Intervirology; 1974; 3(4):232-44. PubMed ID: 4376804
[TBL] [Abstract][Full Text] [Related]
20. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.
McConnell I; Klein G; Lint TF; Lachmann PJ
Eur J Immunol; 1978 Jul; 8(7):453-8. PubMed ID: 211040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
